SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

PROXY FORM

FOR THE 2023 FIRST EXTRAORDINARY GENERAL MEETING
TO BE HELD ON FRIDAY, DECEMBER 15, 2023

I/W *(Note 1)* _____,

(Note 2) _____ b

d d ( ) *(Note 3)* _____ H RMB1.00 ac

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (**Company**), b C a

(a) _____ (add

(Notes 4 & 5) _____. ac a /

a. d d / a d / b a 2023 a d a (**EGM**) C a

b d a. 2:00 . F da , D c b 15, 2023 a Ba , 2/F, L'H a H . 3031 Na B ad, Na D . c.,

S , P ' R b c C a (**PRC**) a d a ad c d a d, ,

a c a d c (**Notice**) C a da d N b 24, 2023 a d EGM a d.

c a c d d a , a a d a c a c a C a c.

N c EGM a d , c d ca , a /

No.	SPECIAL RESOLUTION	FOR *(Note 6)*	AGAINST *(Note 6)*	ABSTAIN *(Note 6)*
1.00	T a d a d a c a a d a d d C a			
	ORDINARY RESOLUTION	**FOR** *(Note 6)*	**AGAINST** *(Note 6)*	**ABSTAIN** *(Note 6)*
2.00	T a d a c a c d H a C a			
	SPECIAL RESOLUTION	**FOR** *(Note 6)*	**AGAINST** *(Note 6)*	**ABSTAIN** *(Note 6)*
3.00	T a d a d a c d. a d d a a. c a ba			

Da : _____ S a ( ) *(Note 7)*: _____

Notes:

1. P a a ( ) **BLOCK CAPITALS**.
2. P a add ( ) **BLOCK CAPITALS**.
3. P a b H a C a d a ( ). c a I b d, b d d. a a H a C a d a ( ).
4. I a a d H a C a (**H Shares Shareholder**) d a. d ad a a a d a b a H S a S a d, b a. d a a d.
5. I a a d C a a d, a d C a a d a a ad add ( ) d d ac d d. I a d, C a a ac a **ANY ALTERATION MADE TO THIS PROXY FORM MUST BE INITIALLED BY THE PERSON(S) WHO SIGNS IT.**
6. **IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "FOR". IF YOU WISH TO VOTE AGAINST A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "AGAINST". IF YOU WISH TO ABSTAIN, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "ABSTAIN".** I d ca a a a d ca / d c a / / ad, ad, c d / a ab a / a b (c d a d) c a b d a . T ab a d b c d ca c a, d a .
7. T b a dd db H S a S a d / a. d a d , . I H S a S a d a c a, d c a b d c. (a) ( ) d a d b a. I ca d, a ad a b a. d ad a EGM, b .
8. T b a d, a a c dc c a. a a, b c d ad d a H S a C a, T c I . S c L d, a. 17/F, Fa Ea . F ac C , 16 Ha c . R ad, H K 24 b a ad .
9. C ad c d a. d a d a a a d db a. a a a a a a a a a P a d d. c a a a. T P a Da a b a d c d a b c a P (c d ca a d c d). R acc a d/ c c. P a Da a ca b ad acc da c PDPO a d a c d b a d . P ac C a c O c T c I . S c L d a ab add .
10. H S a S a d a. d a dc d dc .

PERSONAL INFORMATION COLLECTION STATEMENT

P a Da a a a a a da a d d P a Da a (P ac) O d a c , C a . 486 La H K (**PDPO**), c d ad a add . Y P a Da a a a ba ad c c a. a ad P F (**P**). I a c a, C a a b ab c c. T C a a d c a P a Da a. b d a, H S a S a R a a d/ d a. c d ad a, c a d c a C a c. P a d. c a a a a d db a. a a a a. P a d d. c a a. T P a Da a b a d c d a b c a P (c d ca a d c d). R acc a d/ c c. P a Da a ca b ad acc da c PDPO a d a c d b a d . P ac C a c O c T c I . S c L d a ab add .